Immunogen Inc (DELISTED) (IMGN:DL)
31.23
0.00 (0.00%)
USD |
NASDAQ |
Feb 13, 16:00
Immunogen Research and Development Expense (TTM): 207.75M for Sept. 30, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | 207.75M |
| June 30, 2023 | 219.36M |
| March 31, 2023 | 220.71M |
| December 31, 2022 | 213.37M |
| September 30, 2022 | 203.85M |
| June 30, 2022 | 177.82M |
| March 31, 2022 | 160.99M |
| December 31, 2021 | 151.12M |
| September 30, 2021 | 141.73M |
| June 30, 2021 | 133.26M |
| March 31, 2021 | 121.60M |
| December 31, 2020 | 114.59M |
| September 30, 2020 | 101.07M |
| June 30, 2020 | 97.40M |
| March 31, 2020 | 103.04M |
| December 31, 2019 | 114.52M |
| September 30, 2019 | 132.15M |
| June 30, 2019 | 158.38M |
| March 31, 2019 | 168.52M |
| December 31, 2018 | 174.46M |
| September 30, 2018 | 170.62M |
| June 30, 2018 | 155.06M |
| March 31, 2018 | 151.68M |
| December 31, 2017 | 139.74M |
| September 30, 2017 | 132.80M |
| Date | Value |
|---|---|
| June 30, 2017 | 139.77M |
| March 31, 2017 | 140.54M |
| September 30, 2016 | 145.85M |
| June 30, 2016 | 148.08M |
| March 31, 2016 | 139.86M |
| December 31, 2015 | 129.43M |
| September 30, 2015 | 118.88M |
| June 30, 2015 | 111.77M |
| March 31, 2015 | 107.12M |
| December 31, 2014 | 119.73M |
| September 30, 2014 | 112.95M |
| June 30, 2014 | 106.96M |
| March 31, 2014 | 101.57M |
| December 31, 2013 | 84.61M |
| September 30, 2013 | 85.40M |
| June 30, 2013 | 87.07M |
| March 31, 2013 | 86.21M |
| December 31, 2012 | 81.83M |
| September 30, 2012 | 75.73M |
| June 30, 2012 | 69.19M |
| March 31, 2012 | 67.91M |
| December 31, 2011 | 66.74M |
| September 30, 2011 | 67.19M |
| June 30, 2011 | 63.45M |
| March 31, 2011 | 58.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
97.40M
Minimum
Jun 2020
220.71M
Maximum
Mar 2023
154.04M
Average
146.42M
Median
Research and Development Expense (TTM) Benchmarks
| AbbVie Inc | 7.322B |
| Pfizer Inc | 10.67B |
| Johnson & Johnson | 15.30B |
| Merck & Co Inc | 30.25B |
| Cerevel Therapeutics Holdings Inc | 362.88M |